Supported in part by the UT Southwestern NCI National Clinical Trials Network Lead Academic Site award (UG1 CA233302-01) and the Harold C. Simmons Comprehensive Cancer Center Support Grant No. (3P30 CA 142543-10S3).

Conception and design: All authors

Administrative support: David E. Gerber

Provision of study materials or patients: Christa Braun-Inglis

Collection and assembly of data: Christa Braun-Inglis, Erin L. Williams, Alyssa Macchiaroli, Andrea Denicoff

Data analysis and interpretation: Erin L. Williams, Andrea Denicoff, David E. Gerber

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Better Late Than Never: Fully Incorporating Oncology Advanced Practice Providers Into Cancer Clinical Trials

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Erin L. Williams

Consulting or Advisory Role: Lilly, Genentech/Roche

Alyssa Macchiaroli

Employment: Flatiron Health

David E. Gerber

Stock and Other Ownership Interests: Gilead Sciences

Consulting or Advisory Role: Samsung Bioepis, Catalyst Pharmaceuticals, Mirati Therapeutics, Janssen Oncology, BeiGene, Sanofi, Regeneron

Research Funding: BerGenBio (Inst), Karyopharm Therapeutics (Inst), AstraZeneca (Inst)

Patents, Royalties, Other Intellectual Property: Royalties from Oxford University Press from two books, Royalties from Decision Support in Medicine from the Clinical Decision Support—Oncology online program, Patent pending: Prediction and Treatment of Immunotherapeutic Toxicity (provisional, application number 62/461,455) (Inst)

Uncompensated Relationships: Bristol Myers Squibb

No other potential conflicts of interest were reported.